EVALUATION OF A NEW ELISA PANEL FOR SCREENING OF ATROPHIC GASTRITIS

Abstract

Helicobacter pylori –associated atrophic gastritis is known to be a significant risk factor for gastric cancer. Among the well-known parameters of atrophic gastritis are the levels of serum gastrin-17and pepsinogin I&II, which are biomarkers of gastric antral and corpus mucosal activity, respectively. The aim of the study was to evaluate a new ELISA panel for screening of atrophic gastritis. This study was done in mafraq hospital in the U.A.E. A total of 60 dyspeptic out patients who underwent diagnostic upper gastrointestinal endoscopy with biopsy were recruited to the study. The levels of antibodies to helicobacter pylori and levels of pepsinogenI, pepsinogenII and gastrin-17 were measured using a new ELISA panel. The results of the ELISA panel were compared with result of histology the sensitivity and specificity of the test were calculated . A decrease in serum G-17 levels along with the antral atrophy were observed in patients positive to Helicobacter pylori ELISA test, the serum level of SPGI was also reduced in corpus atrophy irrespective of the presence or absence of the Helicobacter pylori infection. The diagnosis of atrophic gastritis obtained with the blood test panel of G-17, PGI&II and H. pylori antibodies is in a fair agreement with the biopsy findings. Therefore Gastro panel could be used as a tool for non-endoscopic screening of atrophic gastritis